Submitted by Anonymous (not verified) on 20 November 2023 - 11:55
Human medicines European public assessment report (EPAR): Imfinzi, durvalumab, Carcinoma, Non-Small-Cell Lung, Date of authorisation: 21/09/2018, Revision: 18, Status: Authorised
Source: